| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥8.7B | ¥6.4B | +35.8% |
| Operating Income | ¥-51.5B | ¥-91.1B | +43.5% |
| Ordinary Income | ¥-52.9B | ¥-75.4B | +29.8% |
| Net Income | ¥-56.6B | ¥-393.1B | +85.6% |
| ROE | -184.0% | -1823.1% | - |
FY2025 full-year results showed revenue of 8.7 billion yen, up 35.8% YoY, while operating loss was 51.5 billion yen, improving 43.5% from the prior year's loss of 91.1 billion yen. Ordinary loss was 52.9 billion yen, improving 29.8% YoY, and net loss attributable to owners was 56.6 billion yen, improving 85.6% from the prior year's loss of 393.1 billion yen. Despite continued losses, the magnitude of losses narrowed substantially across all profit levels. Total assets increased to 54.0 billion yen from 46.7 billion yen, while total equity improved to 30.8 billion yen from 21.6 billion yen, reflecting capital reinforcement amid persistent operational deficits.
Revenue increased 35.8% YoY to 8.7 billion yen, primarily driven by growth in existing customer relationships. Major customer S.D. Collabo contributed 3.0 billion yen in revenue during the current period. Geographic revenue concentration remained domestic-focused, with over 90% of sales generated in Japan, compared to the prior year when Sweden contributed 75.8 million yen of overseas revenue. The single-segment pharmaceutical business model limits diversification but allows focused resource allocation.
Operating loss narrowed 43.5% to 51.5 billion yen despite revenue growth, indicating that cost structure remains heavily weighted. Research and development expenses totaled 3.6 billion yen, representing a significant portion of revenue and reflecting continued investment in pipeline development. Selling, general and administrative expenses remained elevated relative to the revenue base, constraining margin improvement. Non-recurring factors materially impacted the bottom line, with impairment losses of 20.0 billion yen recorded as extraordinary loss, accounting for approximately 35.4% of the net loss magnitude.
The gap between ordinary loss of 52.9 billion yen and net loss of 56.6 billion yen represents a 6.9% variance, primarily attributable to the extraordinary impairment charge. This non-cash charge reflects asset revaluation but does not affect operating cash generation capacity. Foreign exchange losses of 1.6 billion yen also contributed to non-operating expense, indicating exposure to currency fluctuation.
The performance pattern reflects revenue growth with loss reduction, where top-line expansion is occurring but profitability remains deeply negative due to structural cost burden and one-time asset write-downs. Operating leverage has not yet materialized sufficiently to offset fixed costs and R&D investment.
[Profitability] Operating margin was negative 588.7%, reflecting continued investment phase in pharmaceutical development, while net profit margin stood at negative 647.5%, heavily influenced by the 20.0 billion yen impairment charge. Return on equity was negative 166.6%, improving from more severe negative levels in prior periods as accumulated losses narrowed and equity base strengthened. Return on assets was negative 104.8%, indicating that asset base has not yet generated positive returns. [Cash Quality] Cash and deposits totaled 1.9 billion yen at period end, providing coverage of 0.08 times short-term liabilities. Operating cash flow was negative 5.8 billion yen, representing 1.02 times net loss, indicating that cash consumption tracked closely with accounting losses. Free cash flow was negative 5.7 billion yen, with capital expenditures of 0.1 billion yen against depreciation of 0.5 billion yen, yielding a capex-to-depreciation ratio of 0.27 times. [Investment Efficiency] Asset turnover was 0.16 times, reflecting low revenue generation relative to asset base, typical of development-stage pharmaceutical companies with substantial deferred tax assets and research-related intangibles. Inventory turnover days extended significantly, and cash conversion cycle lengthened, indicating working capital inefficiency. [Financial Health] Equity ratio improved to 57.0% from 46.2% YoY, demonstrating stronger capitalization despite accumulated deficits. Current ratio stood at 195.5% and quick ratio at 185.1%, indicating adequate short-term liquidity. Debt-to-equity ratio was 0.76 times, with liabilities totaling 23.3 billion yen against equity of 30.8 billion yen. Retained earnings deficit of 51.6 billion yen reflects cumulative historical losses.
Cash and deposits decreased 3.8 billion yen YoY to 1.9 billion yen, reflecting continued operational cash consumption. Operating cash outflow of 5.8 billion yen tracked closely with net loss of 5.7 billion yen, yielding an operating CF to net income ratio of 1.02, which indicates that accounting losses are substantially reflected in cash movements. Working capital changes showed accounts payable increasing 0.2 billion yen, suggesting extended payment terms to suppliers, while accounts receivable increased 0.4 billion yen in line with revenue growth. Investing cash outflow of 0.1 billion yen represented limited capital expenditure, well below depreciation of 0.5 billion yen, indicating deferred facility investment. The capex-to-depreciation ratio of 0.27 suggests potential underinvestment in long-term asset renewal. Financing activities provided liquidity support, with equity issuance earlier in the period contributing to the capital base visible in the equity increase from 21.6 billion yen to 30.8 billion yen. Free cash flow of negative 5.7 billion yen indicates ongoing cash consumption that requires external funding or operational improvement to achieve sustainability. Short-term liquidity coverage of 0.08 times requires monitoring, though overall current ratio of 195.5% provides a buffer through other current assets.
Ordinary loss of 52.9 billion yen compared to operating loss of 51.5 billion yen reflects a net non-operating expense contribution of approximately 1.4 billion yen, primarily consisting of foreign exchange losses of 1.6 billion yen partially offset by minor financial income. Non-operating items represent 16.1% of revenue, indicating material impact from currency movements and financial position management. The divergence between ordinary loss and net loss of 3.7 billion yen is primarily attributable to extraordinary impairment losses of 20.0 billion yen, a non-recurring charge that distorts bottom-line earnings. Excluding this extraordinary item, net loss would have been approximately 36.6 billion yen, still substantially negative but more representative of operational performance. Operating cash flow exceeded net loss in absolute terms (both negative), with operating CF of negative 5.8 billion yen against net loss of negative 5.7 billion yen, yielding a ratio of 1.02. This indicates limited divergence between accrual-based earnings and cash realization, suggesting that reported losses are cash-backed rather than driven by non-cash accruals. Accrual ratio of 11.6% exceeds the 10% threshold typically associated with elevated earnings management risk, warranting attention to revenue recognition timing and expense capitalization policies. The substantial R&D expense and impairment charges are appropriately reflected in cash consumption patterns, supporting overall earnings quality despite poor profitability metrics.
Full-year guidance anticipates revenue of 13.3 billion yen, representing 52.2% growth from the prior year. Current period revenue of 8.7 billion yen represents 65.4% progress against this full-year target, indicating that Q4 revenue would need to reach approximately 4.6 billion yen to achieve guidance, or that the guidance may be conservative. Operating loss guidance of 102.3 billion yen represents substantial deterioration from the current period's 51.5 billion yen operating loss, suggesting planned increase in R&D or other strategic expenses. The forecast implies that revenue growth will be accompanied by accelerated cost investment rather than margin improvement. Net loss guidance of 102.5 billion yen similarly indicates expectation of continued substantial deficits. The company forecasts zero dividend per share, consistent with current loss position and cash consumption. This guidance reflects a strategic prioritization of pipeline investment over near-term profitability, typical of development-stage pharmaceutical companies. Investors should monitor execution against revenue targets and whether planned expense increases yield pipeline advancement milestones.
Pipeline development risk represents the primary threat, as R&D expenses of 3.6 billion yen consume 41.1% of revenue with uncertain probability of successful drug approval and commercialization. Clinical trial failures or regulatory setbacks could render development investments unrecoverable and eliminate future revenue potential. Customer concentration risk is substantial, with SD Collabo alone contributing 3.0 billion yen or 34.7% of total revenue, and domestic market representing over 90% of sales. Loss of major customer relationships or pricing pressure from concentrated buyers could severely impact revenue stability. Financial sustainability risk emerges from continued operating cash outflow of 5.8 billion yen against cash reserves of 1.9 billion yen, indicating that current cash resources cover only 0.3 years of operational burn rate. Without achieving profitability or securing additional financing, the company faces potential liquidity constraints within 12 to 18 months.
[Industry Position] (Reference - Proprietary Analysis) The pharmaceutical sector typically exhibits high operating margins of 15-25% for established commercial-stage companies, whereas development-stage biotechnology firms commonly report negative margins during clinical investment phases. This company's operating margin of negative 588.7% reflects development-stage characteristics with limited commercial revenue relative to R&D burden. Revenue growth of 35.8% YoY substantially exceeds typical pharmaceutical industry growth of 5-8%, indicating either recovery from depressed base or successful commercialization acceleration. The equity ratio of 57.0% compares favorably to industry median capital structure, suggesting adequate capitalization cushion for risk absorption. ROE of negative 166.6% cannot be meaningfully compared to profitable peers but improvement from prior periods indicates progress toward eventual positive returns. Asset turnover of 0.16 times falls below pharmaceutical industry median of 0.4-0.6 times, reflecting heavy deferred asset base and pre-revenue pipeline investments. The company's negative free cash flow of 5.7 billion yen is typical for development-stage pharmaceuticals which characteristically consume cash until achieving commercial product launches and scale. Industry comparison suggests the company is in early commercialization phase with operational profile more similar to biotechnology development firms than established pharmaceutical manufacturers. (Industry: Pharmaceutical/Biotechnology Development-Stage, Comparison: Prior fiscal periods and typical industry ranges, Source: Proprietary analysis)
Revenue growth acceleration of 35.8% demonstrates successful customer expansion and potential commercial traction for pharmaceutical offerings, suggesting that market acceptance is improving despite overall loss position. The company's trajectory reflects classic development-stage pharmaceutical characteristics with substantial near-term cash consumption offset by potential long-term value creation if pipeline assets achieve regulatory approval and commercial launch. Extraordinary impairment charge of 20.0 billion yen represents significant one-time asset revaluation that distorts reported net loss; adjusting for this non-recurring item yields more normalized operational loss of approximately 36.6 billion yen, which while substantial, shows improving trend from prior periods. Financial structure with 57.0% equity ratio and 195.5% current ratio provides near-term stability buffer, but cash burn rate of approximately 5.8 billion yen annually against 1.9 billion yen cash reserves indicates potential financing requirement within 12-18 months unless profitability inflection occurs or revenue guidance of 13.3 billion yen materializes with improved margin structure.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.